Evidence map›Paper›PMID 36570799›Full record

ReviewJournal of Taibah University Medical Sciences2023

Understanding the challenges to COVID-19 vaccines and treatment options, herd immunity and probability of reinfection.

Mohammad A I Al-Hatamleh, Mai A Abusalah, Ma'mon M Hatmal, Walhan Alshaer, Suhana Ahmad, Manali H Mohd-Zahid, Engku Nur Syafirah E A Rahman, Chan Y Yean, Iskandar Z Alias, Vuk Uskoković and 1 more

Abstract readReview
In one paragraph

Review in Journal of Taibah University Medical Sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mohammad A I Al-HatamlehDepartment of Immunology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Malaysia.
Mai A AbusalahDepartment of Medical Laboratory Sciences, Faculty of Allied Medical Sciences, Zarqa University, Zarqa, Jordan.
Ma'mon M HatmalDepartment of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, The Hashemite University, Zarqa, Jordan.
Walhan AlshaerCell Therapy Center (CTC), The University of Jordan, Amman, Jordan.
Suhana AhmadDepartment of Immunology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Malaysia.
Manali H Mohd-ZahidDepartment of Chemical Pathology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Malaysia.
Engku Nur Syafirah E A RahmanDepartment of Microbiology and Parasitology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Malaysia.
Chan Y YeanDepartment of Microbiology and Parasitology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Malaysia.
Iskandar Z AliasDepartment of Chemical Pathology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Malaysia.
Vuk UskokovićTardigradeNano LLC, Irvine, CA, USA.
Rohimah MohamudDepartment of Immunology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Malaysia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Unlike pandemics in the past, the outbreak of coronavirus disease 2019 (COVID-19), which rapidly spread worldwide, was met with a different approach to control and measures implemented across affected countries. The lack of understanding of the fundamental nature of the outbreak continues to make COVID-19 challenging to manage for both healthcare practitioners and the scientific community. Challenges to vaccine development and evaluation, current therapeutic options, convalescent plasma therapy, herd immunity, and the emergence of reinfection and new variants remain the major obstacles to combating COVID-19. This review discusses these challenges in the management of COVID-19 at length and highlights the mechanisms needed to provide better understanding of this pandemic.

Indexed as

2019-nCoVConvalescent plasma therapyCoronavirusHerd immunityReinfectionSARS-CoV-2

Identifiers

PMID36570799
PMCPMC9758618

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.